CureVac Sample Clauses

CureVac. Subject to CureVac’s obligations as set forth in paras (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of mRNA-Based vaccine and mRNA-Based antibody products targeting the SARS-CoV-2 Pathogen, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any mRNA-Based vaccine or mRNA-Based antibody targeting the SARS-CoV-2 Pathogen other than: (i) a COVID Product Developed and/or Commercialized under this Agreement, and (ii) the First-Gen COVID Vaccine Products, subject to Section 3.3.7. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party’s Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
Sample 1See All (4)
AutoNDA by SimpleDocs
CureVac. Subject to CureVac's obligations as set forth in items (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of Products targeting a Collaboration Pathogens, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any prophylactic and/or therapeutic mRNA-Based vaccine or mRNA-Based antibody targeting a Collaboration Pathogen other than a Product Developed and/or Commercialized under this Agreement. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
Sample 1Sample 2
CureVac. Overview: Founded in 2000 35, CureVac is a NASDAQ- listed36 biopharmaceutical company headquartered in Germany37. Its revenue in the same nine-month period increased by 304% from €10.6 million in 2019 to €42.8 million during the first nine months of 202038. Product specialisation: Messenger RNA (mRNA) technology (specifically its proprietary technology involving the use of non-chemically modified mRNA for prophylactic vaccines, cancer and antibody 25 European Pharmaceutical Review, “AstraZeneca”, xxxxx://xxx.xxxxxxxxxxxxxxxxxxxxxxxxxxxx.xxx/organisations/astrazeneca/ 26 AstraZeneca, “Contact Information”, xxxxx://xxx.xxxxxxxxxxx.xxx/investor-relations/annual-reports/annual-report-2016/contact-information.html 27 AstraZeneca, “FAQs”, xxxxx://xxx.xxxxxxxxxxx.xxx/investor-relations/faqs.html 28 AstraZeneca, “What science can do - AstraZeneca Annual Report and Form 20-F Information 2020”, xxxxx://xxx.xxxxxxxxxxx.xxx/content/dam/az/Investor_Relations/annual-report-2020/pdf/AstraZeneca_AR_2020.pdf 29 Xxxxx Xxxxxxxxx, “AstraZeneca COVID-19 Vaccine (AZD1222)”, January 27, 2021, xxxxx://xxx.xxx.xxx/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Xxxxxxxxx.pdf 30 European Medicines Agency, “Vaxzevria (previously COVID-19 Vaccine AstraZeneca)”, xxxxx://xxx.xxx.xxxxxx.xx/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca 31 Reuters, “AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine”, June 13, 2020, xxxxx://xxx.xxxxxxx.xxx/article/us-health-coronavirus-vaccines-idUSKBN23K0HW 32 Xxxx Xxxxxxxxxxx, “The Serum Institute of India”, December 8, 2020, Fierce Pharma, xxxxx://xxx.xxxxxxxxxxxx.xxx/special-report/top-10-manufacturers-fight-against-covid-19-serum-institute-india 33 Xxxx Xxxxxxxxxxx, “AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors”, November 23, 2020, Fierce Pharma, xxxxx://xxx.xxxxxxxxxxxx.xxx/manufacturing/astrazeneca-hopes-warmer-storage-needs-for-covid-19-vaccine-will-be-advantage-against 34 Xxxxxx Xxxxx, et al. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology. medRxIV, 10 April 2021. Available online: xxxxx://xxx.xxx/10.1101/2021.04.08.21255103 35 CureVac, “History, How it all began”, xxxxx://xxx.xxxxxxx.xxx/en/about-us/historie-rework/ 36 Xxxxxx Xxxxxx, “XxxxXxx says well on track to request vaccine ...
Sample 1

Related to CureVac

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • First Commercial Sale The term “

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Quality Control A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Commercial Diligence Upon execution of this Agreement, Licensee shall diligently proceed with Commercially Diligent Efforts to develop, manufacture, practice, sell and use the Licensed Products in order to make them readily available to the general public as soon as possible on commercially reasonable terms. Licensee shall continue active, diligent Commercially Diligent Efforts for one or more Licensed Product(s) throughout the term of this Agreement (“Actively Commercializing”). In addition, Licensee shall perform at least the following obligations as part of its due diligence activities hereunder:

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

Time is Money Join Law Insider Premium to draft better contracts faster.